drugset

drugset / Trial / NCT00562575

Evaluation of Safety and Effects of SLx-4090 After Dosing for 14 Days in Subjects With High Triglycerides

NCT00562575 ↗

Phase 2 Completed 24 enrolled Response Pharmaceuticals

RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose is to investigate the effect of oral doses of SLx-4090 over 14 days on subjects with high triglycerides.

Timeline

Start: 2007-05
Primary completion: 2008-02
Completion: 2008-02

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	SLx-4090	Small molecule	—	Oral

Indications